The beneficial effects of zoledronic acid therapy following an acute stroke in rats' by Lee et al.

Bone ◽  
2006 ◽  
Vol 39 (5) ◽  
pp. 1164
Author(s):  
Murat Dincer ◽  
Hakan Harputluoglu ◽  
Kadri Altundag
Keyword(s):  
Zoledronic Acid ◽  
Acute Stroke ◽  
Acid Therapy ◽  
Beneficial Effects

The beneficial effect of intravenous zoledronic acid therapy following an acute stroke in rats

Bone ◽  
2006 ◽  
Vol 39 (2) ◽  
pp. 377-382 ◽  
Author(s):  
Jong In Lee ◽  
Hye Won Kim ◽  
Won Ihl Rhee ◽  
Joo Hyun Park ◽  
Seong Hoon Lim ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Beneficial Effect ◽  
Acute Stroke ◽  
Acid Therapy

scholarly journals Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

2012 ◽  
Vol 367 (18) ◽  
pp. 1714-1723 ◽  
Author(s):  
Steven Boonen ◽  
Jean-Yves Reginster ◽  
Jean-Marc Kaufman ◽  
Kurt Lippuner ◽  
Jose Zanchetta ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Fracture Risk ◽  
Acid Therapy

scholarly journals Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis

2015 ◽  
Vol 8 (8) ◽  
pp. 20
Author(s):  
Abdulmoein E. Al-Agha ◽  
Talal A. Shaikhain ◽  
Abdullah A. Ashour
Keyword(s):  
Zoledronic Acid ◽  
Children And Adolescents ◽  
Pediatric Patients ◽  
Systemic Disease ◽  
Laboratory Data ◽  
University Hospital ◽  
Secondary Osteoporosis ◽  
Fracture Rate ◽  
Acid Therapy ◽  
Positive Effects

<p class="NormalWeb"><strong>BACKGROUND/AIM:</strong> Osteoporosis is a systemic disease characterized by decreased bone density and increased tendency to develop fractures. Osteoporosis in children and adolescents is a rare disease usually secondary to Medical conditions or medications given to children. The condition affects normal bone growth and development and carries with it multiple morbidities (physical and psychological) if not corrected promptly. This study aims to share our experience with Zoledronic Acid Therapy in Pediatric patients with secondary osteoporosis.</p><p class="NormalWeb"><strong>METHOD:</strong> A retrospective study which included 46 patients aged 3 to 18 years. All patients received specific doses of Zoledronic acid and were followed up at King Abdulaziz University Hospital (KAUH) in Jeddah, Saudi Arabia. Clinical and laboratory data were collected for each patient from their files. Adverse events were also recorded.</p><p class="NormalWeb"><strong>RESULTS:</strong> The use of Zoledronic Acid in children and adolescents appears to be statically significant reduce fracture rate (p=0.005), bone turnover markers (Osteocalcin p= 0.003, CTX p= 0.008) and pain frequency in symptomatic individuals (p=0.000). Careful selection of cases is required to provide maximum benefits compared to risks associated with therapy.</p><p class="NormalWeb"><strong>CONCLUSION:</strong> This study demonstrates that Zoledronic acid has positive effects on clinical outcome and bone marker level as well as quality of life for Pediatric patients with Osteoporosis and their families, with no long-term side effects.</p>

Normalization of bone markers and improved survival during zoledronic acid therapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9013-9013 ◽  
Author(s):  
A. Lipton ◽  
R. Cook ◽  
R. E. Coleman ◽  
P. Major ◽  
E. Terpos ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Metastases ◽  
Lower Risk ◽  
Type I Collagen ◽  
Continuous Variable ◽  
Type I ◽  
Acid Therapy ◽  
Relative Risks ◽  
Skeletal Related Events ◽  
Tumor Types

9013 Background: In patients (pts) with bone metastases, elevated N-telopeptide of type I collagen (NTX) levels correlate with increased relative risks (RR) of skeletal-related events (SREs), disease progression, and death (Brown et al. J Natl Cancer Inst. 2005;97:59–69; Coleman et al. J Clin Oncol. 2005;23:4925–4935). Therefore, we conducted an exploratory analysis of 3 large, randomized, controlled trials to investigate whether reductions in NTX levels by treatment with zoledronic acid (ZOL) correspond with decreased risks of SREs and death. Methods: Urinary NTX was measured at baseline and at 3 months in pts with bone metastases from breast (BC; n = 379), prostate (PC; n = 314), or lung cancer and other solid tumors (LC/OST; n = 204) who received ZOL for up to 24 months. Pts were stratified by baseline NTX levels (normal, < 64 nmol/mmol creatinine; elevated, = 64 nmol/mmol creatinine). Results: Approximately 50% of pts had elevated baseline NTX, and NTX normalization occurred within 3 months of ZOL treatment in 81% of pts with BC or LC/OST and in 70% of PC pts. For all tumor types, NTX normalization in response to ZOL correlated with reduced risk of first SRE and death compared with pts whose NTX did not normalize ( Table ). Further analyses using NTX level as a continuous variable revealed that, for all tumor types, any reduction in NTX levels correlated with lower risk of first SRE and death regardless of baseline NTX level. Conclusions: Pts whose NTX normalized on ZOL at 3 months had a lower risk of first SRE and death compared with pts whose elevated baseline NTX did not normalize. Regardless of baseline NTX level, a reduction in NTX over 3 months (absolute and % change) provided a continuum of SRE risk reduction and survival benefit. No significant financial relationships to disclose. [Table: see text]

Use of zoledronic acid therapy–associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 58-58
Author(s):  
Julia Warr ◽  
David Yam ◽  
Shannon Goodall ◽  
Leah VanDraanen ◽  
Angie Giotis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Chart Review ◽  
Symptom Control ◽  
Castration Resistant Prostate Cancer ◽  
Acid Therapy ◽  
Patient Demographics ◽  
Castration Resistant ◽  
Late Event ◽  
Grade 3

58 Background: Zoledronic acid (ZOL) therapy is associated with severe (i.e., grade 3/4 according to CTCAEv4.0) hypocalcemia and hypophosphatemia in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) to bone. However, as opposed to the distinct clinical picture of hypocalcemia, the symptoms of hypophosphatemia are less pathognomonic. Furthermore, the rate of hypophosphatemia is not regularly reported. Methods: To characterize the rate and circumstances of severe hypophosphatemia in mCRPC patients undergoing ZOL therapy, we identified mCRPC patients receiving at least 3 doses of ZOL therapy at our Centre between 2004 and 03/2011. Patient demographics, disease and laboratory parameters were extracted by using the Oncology Symptom Control and Information Resource database, and by means of manual chart review. Results: 11 of 112 patients (10%) developed grade 3/4 hypophosphatemia (nadir) after 241±223 days (mean±SD) following the first dose of ZOL. Only one patient presented with concomitant severe hypocalcemia. Interestingly, the hypophosphatemia nadir coincided with rising PSA readings in 9 out of 10 informative patients. Furthermore, ZOL-associated severe hypophosphatemia identified mCRPC patients with worse outcome (time from CRPC diagnosis to death 628±317 days, versus 901±526 days in CRPC patients without severe ZOL-associated hypophosphatemia, p < 0.028). Conclusions: 10% of mCRPC patients undergoing ZOL therapy presented with grade 3/4 hypophosphatemia. While hypocalcemia usually occurs within the first 6 months of ZOL therapy, ZOL-associated severe hypophosphatemia is a relatively late event. It appears to occur at the time of disease progression and is associated with a poor outcome.

Sign in / Sign up

Export Citation Format

Share Document